advertisement
 

  Back to Polls Poll Results

Poll Results

 

Which insulins do you or your child use?

 
 

Vote for all that apply

 
 

Short acting insulins

 
     

NovoLog / Novorapid

 
 

37%

 

  224

 
     

Humalog

 
 

17%

 

  105

 
     

Apidra

 
 

4%

 

  27

 
     

Regular / Actrapid / Velosulin

 
 

1%

 

  4

 
     

Other short acting insulin

 
 

1%

 

  1

 
 

Long acting insulins

 
     

Lantus

 
 

28%

 

  168

 
     

Levemir

 
 

3%

 

  21

 
     

NPH / Isophane / Insulatard

 
 

5%

 

  30

 
     

Other long acting insulin

 
 

1%

 

  2

 
 

Other

 
     

Premixed (70/30, etc.)

 
 

1%

 

  5

 
     

Other insulin

 
 

1%

 

  3

 
     

Don't use insulin

 
 

1%

 

  1

 


Total votes: 591

 

Which insulins do you or your child use?

Poll dates: January 21 - 28, 2009
Total Votes: 591

Insulin users today have a great variety of products from which to choose. In the past few years, two fast-acting analogs (NovoLog and Humalog) and one long-acting analog (Lantus) have been introduced and have changed the way many people use insulin. The use of Regular insulin among our readers has dropped off to just one percent. NPH use has dropped too, from 32% in 2000 to just 5% in 2009 (up from 3% in 2008).

This table shows readers' answers to this survey over the past years:

  Answer     Jan 2009     Jan 2008     Jan 2007     Jan 2006     Jan 2005     Jan 2004     Jan 2003     Jan 2002     Mar 2000  
Short acting insulins
NovoLog 38% 35% 33% 28% 27% 26% 12% 3% --
Humalog 18% 19% 17% 20% 22% 26% 34% 37% 35%
Regular 1% 1% 1% 1% 1% 2% 3% 4% 12%
Apidra 5% 1% 1% 1% 1% -- -- -- --
Long acting insulins
Lantus 28% 30% 31% 32% 27% 21% 17% 11% --
Levemir 4% 4% 4% 2% 1% -- -- -- --
NPH 5% 3% 6% 8% 14% 16% 22% 28% 32%
Lente -- 0% 1% 1% 1% 1% 1% 3% 4%
Ultralente -- 1% 1% 1% 1% 1% 2% 5% 7%
Other
Premixed 1% 1% 1% 1% 1% 1% 2% 2% 5%
Other insulin 1% 2% 1% 1% 1% 1% 2% 2% 2%
Percentages based on use compared with all responses

Looking at answers in the short-acting and long-acting insulins shows a dramatic change since 2000. The following graphs illustrate the rapid increase in use of insulin analogs and the concurrent decline in the use of Regular and NPH.

Rapid Acting Insulin Use

The rise in the use of NovoLog has been particularly significant since it was introduced in 2002. Among users of rapid-acting insulin, NovoLog is used by almost two-thirds of our visitors (62%), while use of Humalog has declined to less than one-third (29%). Apidra, new to the US market in 2006, now has 7% of rapid acting insulin uses. The use of Regular continues to decline.

Graph
Data within rapid-acting insulin only illustrating the widespread use of NovoLog among CWD visitors

Graph
Data for rapid-acting insulin among all responses

Long Acting Insulin Use

As of January 2009, more CWD visitors report using Lantus than any other long acting insulin by a wide margin. This year, 76% of people who use long acting insulin report using Lantus. The use of NPH continues to decline and and now stands at 14% for people who use long acting insulin. Levemir, new in 2005, is used by 10%. Given the clinical benefits of using Lantus or Levemir over NPH, it's no surprise to see the rapid decline in use of NPH. (See our page about Care Suggestions for citations to studies about NPH.)

Graph
Data for long-acting insulin only showing the continuing decline in the use of NPH insulin

Graph
Data for long-acting insulin among all responses

[Download an Excel spreadsheet with the data and graphs from this poll]

[Return to the current poll]



                 
  Home Return to Top

Last Updated: Wednesday January 28, 2009 13:02:52
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.